Featured Research

from universities, journals, and other organizations

Sedative May Have Better Outcomes Than Common Medication For ICU Patients On Respirator

Date:
December 12, 2007
Source:
JAMA and Archives Journals
Summary:
Intensive care unit patients on respirators who were sedated with the drug dexmedetomidine had more days alive without delirium or coma and better sedation compared to patients treated with the recommended drug lorazepam, according to a study in the Dec. 12 issue of JAMA.

Intensive care unit patients on respirators who were sedated with the drug dexmedetomidine had more days alive without delirium or coma and better sedation compared to patients treated with the recommended drug lorazepam, according to a study in the December 12 issue of JAMA.

Related Articles


Benzodiazepine drugs, such as lorazepam, are routinely administered to mechanically ventilated (respirators) patients to reduce pain and anxiety and to allow patients to tolerate invasive procedures in the intensive care unit (ICU). But these medications may also increase mechanical ventilation time, ICU length of stay and the risk of developing acute brain dysfunction, i.e., delirium and coma, according to background information in the article. The medication dexmedetomidine induces sedation via different central nervous system receptors than the benzodiazepine drugs and may lower the risk of acute brain dysfunction.

Pratik P. Pandharipande, M.D., M.S.C.I., of Vanderbilt University Schools of Medicine and Nursing, Nashville, Tenn., and colleagues conducted a study to determine if dexmedetomidine, when compared with benzodiazepine drugs, reduces the duration of delirium and coma while effectively sedating mechanically ventilated ICU patients. The randomized controlled trial included 106 adult ICU patients who were mechanically ventilated between August 2004 and April 2006. Patients were sedated with dexmedetomidine or lorazepam for as many as 120 hours.

The researchers found that dexmedetomidine patients had more days alive without delirium or coma (median [midpoint], 7 vs. 3). About 30 percent fewer patients experienced coma in the dexmedetomidine group than in the lorazepam group (63 percent vs. 92 percent). Nonsignificant differences were noted between the dexmedetomidine and lorazepam groups in death at 28-days (17 percent vs. 27 percent) and ventilator-free days (22 days vs. 18 days alive and free of mechanical ventilation).

A higher but nonsignificant percentage of patients in the dexmedetomidine group were able to complete post-ICU neuropsychological testing. Patients administered dexmedetomidine spent more time near the targeted level of sedation compared with patients sedated with lorazepam (median percentage of days, 80 percent vs. 67 percent). The 12-month time to death in the dexmedetomidine vs. the lorazepam group was 363 vs. 188 days, respectively.

"In this double-blind, randomized controlled trial, dexmedetomidine was more effective than lorazepam for achieving sustained sedation of mechanically ventilated medical and surgical ICU patients. Dexmedetomidine-treated ICU patients had 4 more days alive and without delirium or coma, significantly higher accuracy at meeting the stated sedation goals, and no added cost of care, as measured using data obtained at the largest enrolling site," the authors conclude.


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Cite This Page:

JAMA and Archives Journals. "Sedative May Have Better Outcomes Than Common Medication For ICU Patients On Respirator." ScienceDaily. ScienceDaily, 12 December 2007. <www.sciencedaily.com/releases/2007/12/071211234055.htm>.
JAMA and Archives Journals. (2007, December 12). Sedative May Have Better Outcomes Than Common Medication For ICU Patients On Respirator. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2007/12/071211234055.htm
JAMA and Archives Journals. "Sedative May Have Better Outcomes Than Common Medication For ICU Patients On Respirator." ScienceDaily. www.sciencedaily.com/releases/2007/12/071211234055.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com
From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) — The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins